Literature DB >> 30108949

Conformationally restricted benzothienoazepine respiratory syncytial virus inhibitors: their synthesis, structural analysis and biological activities.

Euan A F Fordyce1, S Fraser Hunt1, Damien Crepin1, Stuart T Onions1, Guillaume F Parra1, Chris J Sleigh1, John King-Underwood2, Harry Finch3, John Murray3.   

Abstract

Atropisomeric drug substances are known to have different biological properties. Compounds containing the N-benzoylbenzazepine motif have been shown to exhibit energetically restricted rotation around the Ar(CO)N axis. Herein we report, for the first time, the synthesis, physical characterisation and anti-viral profiles of a series of C-4 and C-5 methylated thieno-benzazepines. NMR analysis reveals that incorporation of a single additional substituent at either of these loci influences the conformational dynamics of the azepine ring system. In the case of the C-5 alkyl analogues, the influence of the new stereocentre is so pronounced that its absolute configuration determines which unique atropisomer is obtained following the generation of the benzazepine nucleus. Screening of the alkylated derivatives for their anti-respiratory syncytial virus (RSV) activity indicates that the desired viral pathogenicity is strongly associated with the conformation adopted by the modified tricyclic scaffolds. This is particularly evident in the case of the C-5 homologues in which one atropisomer was found to be potently active and the other essentially inert. These results provide compelling evidence that we have determined the bioactive conformation shared by RSV inhibitors that employ the thienobenazapine nucleus as their core molecular architecture. Furthermore, the understanding obtained from these studies may make it possible to design improved agents against RSV infection in the future.

Entities:  

Year:  2018        PMID: 30108949      PMCID: PMC6072213          DOI: 10.1039/c8md00033f

Source DB:  PubMed          Journal:  Medchemcomm        ISSN: 2040-2503            Impact factor:   3.597


  13 in total

Review 1.  The challenge of atropisomerism in drug discovery.

Authors:  Jonathan Clayden; Wesley J Moran; Paul J Edwards; Steven R LaPlante
Journal:  Angew Chem Int Ed Engl       Date:  2009       Impact factor: 15.336

2.  Atropisomerism in the vaptan class of vasopressin receptor ligands: the active conformation recognized by the receptor.

Authors:  Hidetsugu Tabata; Jun Nakagomi; Daisuke Morizono; Tetsuta Oshitari; Hideyo Takahashi; Hideaki Natsugari
Journal:  Angew Chem Int Ed Engl       Date:  2011-02-24       Impact factor: 15.336

Review 3.  Assessing atropisomer axial chirality in drug discovery and development.

Authors:  Steven R Laplante; Lee D Fader; Keith R Fandrick; Daniel R Fandrick; Oliver Hucke; Ray Kemper; Stephen P F Miller; Paul J Edwards
Journal:  J Med Chem       Date:  2011-09-15       Impact factor: 7.446

4.  Progress and developments in the turbo Grignard reagent i-PrMgCl·LiCl: a ten-year journey.

Authors:  Robert Li-Yuan Bao; Rong Zhao; Lei Shi
Journal:  Chem Commun (Camb)       Date:  2015-02-25       Impact factor: 6.222

Review 5.  Recent encounters with atropisomerism in drug discovery.

Authors:  Peter W Glunz
Journal:  Bioorg Med Chem Lett       Date:  2017-12-06       Impact factor: 2.823

6.  Tolvaptan-Type Vasopressin Receptor Ligands: Important Role of Axial Chirality in the Active Form.

Authors:  Hidetsugu Tabata; Tetsuya Yoneda; Tetsuta Oshitari; Hideyo Takahashi; Hideaki Natsugari
Journal:  J Med Chem       Date:  2017-05-16       Impact factor: 7.446

7.  Murrastifoline-F: first total synthesis, atropo-enantiomer resolution, and stereoanalysis of an axially chiral N,C-coupled biaryl alkaloid.

Authors:  G Bringmann; S Tasler; H Endress; J Kraus; K Messer; M Wohlfarth; W Lobin
Journal:  J Am Chem Soc       Date:  2001-03-28       Impact factor: 15.419

8.  Preclinical Characterization of PC786, an Inhaled Small-Molecule Respiratory Syncytial Virus L Protein Polymerase Inhibitor.

Authors:  Matthew Coates; Daniel Brookes; Young-In Kim; Heather Allen; Euan A F Fordyce; Elizabeth A Meals; Thomas Colley; Claire-Lise Ciana; Guillaume F Parra; Vladimir Sherbukhin; Jennifer A Stockwell; Jennifer C Thomas; S Fraser Hunt; Lauren Anderson-Dring; Stuart T Onions; Lindsey Cass; Peter J Murray; Kazuhiro Ito; Pete Strong; John P DeVincenzo; Garth Rapeport
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

Review 9.  The significance of chirality in drug design and development.

Authors:  W H Brooks; W C Guida; K G Daniel
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

10.  7-Chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoyl-amino)benzoyl ]-2,3,4,5-tetrahydro-1H-1-benzazepine (OPC-41061): a potent, orally active nonpeptide arginine vasopressin V2 receptor antagonist.

Authors:  K Kondo; H Ogawa; H Yamashita; H Miyamoto; M Tanaka; K Nakaya; K Kitano; Y Yamamura; S Nakamura; T Onogawa; T Mori; M Tominaga
Journal:  Bioorg Med Chem       Date:  1999-08       Impact factor: 3.641

View more
  1 in total

1.  Substituted N-(4-amino-2-chlorophenyl)-5-chloro-2-hydroxybenzamide analogues potently inhibit respiratory syncytial virus (RSV) replication and RSV infection-associated inflammatory responses.

Authors:  Jimin Xu; Wenzhe Wu; Haiying Chen; Yu Xue; Xiaoyong Bao; Jia Zhou
Journal:  Bioorg Med Chem       Date:  2021-04-18       Impact factor: 3.461

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.